X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (106) 106
index medicus (90) 90
hematology (72) 72
male (61) 61
arabinonucleosides - administration & dosage (58) 58
female (57) 57
oncology (53) 53
adenine nucleotides - administration & dosage (47) 47
clofarabine (46) 46
adult (44) 44
middle aged (38) 38
arabinonucleosides - adverse effects (36) 36
arabinonucleosides - therapeutic use (34) 34
transplantation (34) 34
acute myeloid-leukemia (30) 30
adolescent (30) 30
child (30) 30
leukemia (30) 30
cancer (29) 29
aged (28) 28
arabinonucleosides - pharmacology (27) 27
chemotherapy (27) 27
recurrence (27) 27
antineoplastic combined chemotherapy protocols - therapeutic use (26) 26
immunology (26) 26
adenine nucleotides - adverse effects (25) 25
animals (24) 24
child, preschool (24) 24
acute lymphoblastic-leukemia (23) 23
antimitotic agents (23) 23
antineoplastic agents (23) 23
hematology, oncology and palliative medicine (23) 23
children (22) 22
treatment outcome (22) 22
health aspects (21) 21
adenine nucleotides - therapeutic use (20) 20
hematopoietic stem cells (20) 20
leukemia, myeloid, acute - drug therapy (20) 20
research (20) 20
stem cells (20) 20
young adult (20) 20
antineoplastic agents - therapeutic use (19) 19
article (19) 19
care and treatment (19) 19
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
leukemia, myeloid, acute - mortality (18) 18
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (17) 17
transplantation, homologous (17) 17
cytarabine (16) 16
hematopoietic stem cell transplantation (16) 16
nelarabine (16) 16
adults (15) 15
aml (15) 15
bone-marrow-transplantation (15) 15
pharmacology & pharmacy (15) 15
pediatrics (14) 14
remission induction (14) 14
acute lymphocytic leukemia (13) 13
acute myelogenous leukemia (13) 13
antineoplastic combined chemotherapy protocols - administration & dosage (13) 13
cyclophosphamide (13) 13
infant (13) 13
leukemia, myeloid, acute - therapy (13) 13
mice (13) 13
myelodysplastic syndrome (13) 13
survival analysis (13) 13
transplantation conditioning - methods (13) 13
cytarabine - administration & dosage (12) 12
disease-free survival (12) 12
etoposide (12) 12
pediatric-patients (12) 12
stem-cell transplantation (12) 12
clinical trials (11) 11
cyclophosphamide - administration & dosage (11) 11
relapse (11) 11
stem cell transplantation (11) 11
survival rate (11) 11
t cells (11) 11
acute lymphatic leukemia (10) 10
analysis (10) 10
dose-response relationship, drug (10) 10
fludarabine (10) 10
phase-i (10) 10
prognosis (10) 10
retrospective studies (10) 10
salvage therapy (10) 10
2-chloro-9-adenine (9) 9
acute myeloid leukemia (9) 9
adenine nucleotides - pharmacology (9) 9
busulfan (9) 9
busulfan - administration & dosage (9) 9
combination (9) 9
follow-up studies (9) 9
hemic and lymphatic diseases (9) 9
oncology, experimental (9) 9
remission (9) 9
ribonucleotide reductase (9) 9
salvage therapy - methods (9) 9
acute lymphoblastic leukemia (8) 8
antimetabolites, antineoplastic - therapeutic use (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes, ISSN 0012-1797, 04/2017, Volume 66, Issue 4, pp. 908 - 919
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2012, Volume 130, Issue 2, pp. 468 - 472
Journal Article
Annals of Hematology, ISSN 0939-5555, 3/2014, Volume 93, Issue 3, pp. 493 - 498
The frequency of breakthrough invasive fungal diseases (IFDs) during echinocandin therapy is unclear. We retrospectively analyzed 534 hematologic patients... 
Echinocandin | Breakthrough invasive fungal infections | Oncology | Medicine & Public Health | Hematology | INFECTIONS | HEMATOLOGY | MYCOSES | Lung Diseases, Fungal - prevention & control | Lipopeptides - therapeutic use | Lung Diseases, Fungal - epidemiology | Humans | Fusarium - drug effects | Antibiotic Prophylaxis | Cross Infection - immunology | Antifungal Agents - therapeutic use | Lung Diseases, Fungal - virology | Candidiasis, Invasive - virology | Fusariosis - virology | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Retrospective Studies | Candida - immunology | Cross Infection - virology | Cross Infection - epidemiology | Hematologic Diseases - complications | Lung Diseases, Fungal - immunology | Candidiasis, Invasive - epidemiology | Cross Infection - prevention & control | Fusariosis - epidemiology | Risk Factors | Adenine Nucleotides - therapeutic use | Fusariosis - prevention & control | China - epidemiology | Hematologic Diseases - virology | Arabinonucleosides - adverse effects | Candida - isolation & purification | Arabinonucleosides - therapeutic use | Hematologic Diseases - immunology | Adenine Nucleotides - adverse effects | Hematologic Diseases - therapy | Antimetabolites, Antineoplastic - therapeutic use | Fusarium - immunology | Candidiasis, Invasive - immunology | Antimetabolites, Antineoplastic - adverse effects | Echinocandins - therapeutic use | Fusariosis - immunology | Candida - drug effects | Candidiasis, Invasive - prevention & control | Immunocompromised Host | Fusarium - isolation & purification | Cohort Studies | Mycoses | Care and treatment | Risk factors
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 09/2017, Volume 23, Issue 9, pp. 1491 - 1497
In patients with relapsed or refractory (r/r) acute myeloid leukemia (AML), allogeneic hematopoietic stem cell transplantation (HSCT) is considered to be the... 
Clofarabine | Comorbidity | Acute myeloid leukemia | Hematopoietic stem cell transplantation | AML | PLUS CYTARABINE | GERIATRIC ASSESSMENT | COMPLETE REMISSION | EARLY DEATH | HIGH-DOSE CYTARABINE | 2ND REMISSION | IMMUNOLOGY | MYELODYSPLASTIC SYNDROME | TRANSPLANTATION | OLDER PATIENTS | ILLNESS RATING-SCALE | HEMATOLOGY | Recurrence | Prognosis | Cytarabine - therapeutic use | Humans | Middle Aged | Cardiovascular Diseases - therapy | Lung Diseases - mortality | Male | Lung Diseases - therapy | Leukemia, Myeloid, Acute - immunology | Melphalan - therapeutic use | Cardiovascular Diseases - pathology | Transplantation, Homologous | Cardiovascular Diseases - mortality | Adult | Female | Transplantation Conditioning - methods | Leukemia, Myeloid, Acute - therapy | Kidney Diseases - pathology | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Kidney Diseases - mortality | Adenine Nucleotides - therapeutic use | Arabinonucleosides - therapeutic use | Kidney Diseases - immunology | Leukemia, Myeloid, Acute - mortality | Lung Diseases - immunology | Cardiovascular Diseases - immunology | Antimetabolites, Antineoplastic - therapeutic use | Survival Analysis | Kidney Diseases - therapy | Aged | Lung Diseases - pathology | Salvage Therapy - methods | Care and treatment | Relapse | Stem cells | Transplantation | Hematopoietic stem cells | Diseases | Analysis
Journal Article
Haematologica, ISSN 0390-6078, 09/2014, Volume 99, Issue 9, pp. 1486 - 1491
We prospectively evaluated the safety and efficacy of a clofarabine, intravenous busulfan and antithymocyte globulin-based reduced-toxicity conditioning... 
ALLO-SCT | EUROPEAN-GROUP | OLDER PATIENTS | ACUTE LYMPHOBLASTIC-LEUKEMIA | ACUTE MYELOID-LEUKEMIA | MARROW-TRANSPLANTATION | DONOR TRANSPLANTATION | HEMATOLOGY | 1ST COMPLETE REMISSION | MYELODYSPLASTIC SYNDROME | HEMATOLOGIC MALIGNANCIES | Myeloablative Agonists - therapeutic use | Recurrence | Graft Survival - immunology | Leukemia, Biphenotypic, Acute - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Humans | Middle Aged | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Leukemia, Myeloid, Acute - immunology | Transplantation, Homologous | Myelodysplastic Syndromes - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | Antilymphocyte Serum - therapeutic use | Adult | Female | Transplantation Conditioning - methods | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Leukemia, Biphenotypic, Acute - mortality | Leukemia, Myeloid, Acute - therapy | Leukemia, Biphenotypic, Acute - pathology | Busulfan - therapeutic use | Drug Administration Schedule | Leukemia, Biphenotypic, Acute - immunology | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Adenine Nucleotides - therapeutic use | Arabinonucleosides - therapeutic use | Leukemia, Myeloid, Acute - mortality | Myelodysplastic Syndromes - mortality | Survival Analysis | Aged | Myelodysplastic Syndromes - pathology | Myelodysplastic Syndromes - immunology | Index Medicus | Life Sciences | Medication | Human health and pathology | Hematology | Pharmaceutical sciences | Cancer
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2014, Volume 165, Issue 4, pp. 504 - 509
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 3, pp. 344 - 356
Abstract Melphalan remains the most widely used agent in preparative regimens for hematopoietic stem cell transplantation (SCT). From its initial discovery... 
Hematology, Oncology and Palliative Medicine | Stem cell transplantation | Conditioning regimens | Melphalan | DIAGNOSED MULTIPLE-MYELOMA | BONE-MARROW-TRANSPLANTATION | LONG-TERM OUTCOMES | IMMUNOLOGY | 1ST COMPLETE REMISSION | TRANSPLANTATION | CORD BLOOD TRANSPLANTATION | INTENSITY ALLOGENEIC TRANSPLANTATION | LIGHT-CHAIN AMYLOIDOSIS | ACUTE LYMPHOBLASTIC-LEUKEMIA | NON-HODGKINS-LYMPHOMA | HIGH-DOSE MELPHALAN | HEMATOLOGY | Hematologic Neoplasms - therapy | Myeloablative Agonists - therapeutic use | Myeloablative Agonists - pharmacology | Graft Survival - immunology | Humans | Pyrazines - administration & dosage | Multiple Myeloma - immunology | Transplantation, Autologous | Hematologic Neoplasms - pathology | Melphalan - therapeutic use | Transplantation, Homologous | Thalidomide - analogs & derivatives | Arabinonucleosides - administration & dosage | Multiple Myeloma - therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Melphalan - pharmacology | Boronic Acids - administration & dosage | Transplantation Conditioning - methods | Adenine Nucleotides - administration & dosage | Bortezomib | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Alemtuzumab | Thalidomide - administration & dosage | Multiple Myeloma - pathology | Hematologic Neoplasms - immunology | Graft Survival - drug effects | Transplantation | Lymphomas | Hematopoietic stem cells | Multiple myeloma | Stem cells | Index Medicus | melphalan | stem cell transplantation | conditioning regimens
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2012, Volume 18, Issue 6, pp. 913 - 921
We conducted a phase I-II study of transplantation conditioning with clofarabine-melphalan-alemtuzumab for patients with advanced hematologic malignancies. Ten... 
Hematology, Oncology and Palliative Medicine | Clofarabine | Phase II | Conditioning | Transplant | CARDIAC TOXICITY | RISK | ACUTE MYELOID-LEUKEMIA | CYTARABINE | IMMUNOLOGY | MYELODYSPLASTIC SYNDROME | FLUDARABINE | TRANSPLANTATION | PEDIATRIC-PATIENTS | CLINICAL-TRIALS | NON-HODGKINS-LYMPHOMA | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Hematologic Neoplasms - therapy | Lymphoma, Non-Hodgkin - immunology | Recurrence | Age Factors | Hematologic Neoplasms - mortality | Humans | Middle Aged | Male | Risk | Antineoplastic Agents - therapeutic use | Leukemia, Myeloid, Acute - immunology | Melphalan - therapeutic use | Transplantation, Homologous | Melphalan - adverse effects | Antineoplastic Agents - adverse effects | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Acute Kidney Injury - etiology | Leukemia, Myeloid, Acute - therapy | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Glomerular Filtration Rate | Adenine Nucleotides - therapeutic use | Alemtuzumab | Acute Kidney Injury - physiopathology | Arabinonucleosides - adverse effects | Arabinonucleosides - therapeutic use | Adenine Nucleotides - adverse effects | Leukemia, Myeloid, Acute - mortality | Acute Kidney Injury - mortality | Lymphoma, Non-Hodgkin - therapy | Survival Analysis | Aged | Lymphoma, Non-Hodgkin - mortality | Hematologic Neoplasms - immunology | Transplantation Conditioning | Index Medicus
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2011, Volume 17, Issue 6, pp. 893 - 900
Although a combination of i.v. busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning program for acute myelogenous... 
Hematology, Oncology and Palliative Medicine | AML | Allogeneic | Stem Cell Transplantation | Fludarabine | CML | IV Busulfan | Clofarabine | MDS | TOTAL-BODY IRRADIATION | PREPARATIVE REGIMEN | BONE-MARROW-TRANSPLANTATION | IMMUNOLOGY | VERSUS-HOST-DISEASE | TRANSPLANTATION | ALLOGENEIC TRANSPLANTATION | PLUS CYCLOPHOSPHAMIDE | HEPATIC VENOOCCLUSIVE DISEASE | DAILY INTRAVENOUS BUSULFAN | MYELODYSPLASTIC-SYNDROME | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Injections, Intravenous | Humans | Middle Aged | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - administration & dosage | Leukemia, Myeloid, Acute - immunology | Busulfan - administration & dosage | Transplantation, Homologous | Arabinonucleosides - administration & dosage | Graft vs Host Disease - mortality | Female | Adenine Nucleotides - administration & dosage | Immunosuppressive Agents - administration & dosage | Leukemia, Myeloid, Acute - therapy | Rabbits | Drug Administration Schedule | Leukemia, Myeloid, Acute - pathology | Hematopoietic Stem Cell Transplantation | Vidarabine - analogs & derivatives | Remission Induction | Drug Synergism | Leukemia, Myeloid, Acute - mortality | Animals | Tacrolimus | Survival Analysis | Cell Line, Tumor | Myeloablative Agonists - administration & dosage | Graft vs Host Disease - prevention & control | Antilymphocyte Serum | Vidarabine - administration & dosage | Transplantation Conditioning | Index Medicus | Allogeneic Stem Cell Transplantation
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2013, Volume 19, Issue 7, pp. 1124 - 1126
Journal Article
British Journal of Haematology, ISSN 0007-1048, 07/2012, Volume 158, Issue 2, pp. 198 - 207
Summary The prognosis of patients with relapsed and refractory acute leukaemia (RRAL) is very poor. Forty patients with RRAL were enroled [28 acute myeloid... 
cyclophosphamide | clofarabine | acute myeloid leukaemia | acute lymphoblastic leukaemia | refractory leukaemia | Acute myeloid leukaemia | Cyclophosphamide | Clofarabine | Acute lymphoblastic leukaemia | Refractory leukaemia | ACUTE MYELOGENOUS LEUKEMIA | ACUTE LYMPHOCYTIC-LEUKEMIA | ACUTE MYELOID-LEUKEMIA | CYTARABINE | INDUCTION | RIBONUCLEOTIDE REDUCTASE | INHIBITION | ACUTE LYMPHOBLASTIC-LEUKEMIA | SALVAGE THERAPY | 2-CHLORO-9-(2-DEOXY-2-FLUORO-BETA-D-ARABINOFURANOSYL)ADENINE | HEMATOLOGY | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology | Prospective Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Leukemia, Myeloid, Acute - immunology | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Dose-Response Relationship, Drug | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Arabinonucleosides - administration & dosage | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Adenine Nucleotides - administration & dosage | Drug Administration Schedule | Treatment Outcome | Adenine Nucleotides - therapeutic use | Arabinonucleosides - adverse effects | Remission Induction | Arabinonucleosides - therapeutic use | Adenine Nucleotides - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Salvage Therapy - methods | Salvage | Acute lymphatic leukemia | Leukemia | Neutrophils | Fatalities | Adults | Patients | Recovery | Deoxyribonucleic acid--DNA | Infection | Prognosis | DNA | Clinical trials | Remission | Leukocytes (neutrophilic) | Age | Blood
Journal Article